Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
34.06 ^USD	+0.89%		-19.38%	-18.09%

Jan. 19	Moderna Lands $590 Million for Bird Flu Vaccine Development in US	MT
Jan. 17	Moderna Gets $590 Million of Federal Funding For Bird Flu Vaccine -- Update	DJ

HSBC Upgrades Moderna to Buy From Hold, Adjusts Price Target to $58 From $82

November 18, 2024 at 05:47 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Moderna, Inc.

Moderna Lands $590 Million for Bird Flu Vaccine Development in US	Jan. 19	MT
Moderna Gets $590 Million of Federal Funding For Bird Flu Vaccine -- Update	Jan. 17	DJ
Moderna Gets $590 Million From US Government for Influenza Vaccine Program; Shares Rise After Hours	Jan. 17	MT
US awards Moderna $590 million for bird flu vaccine development	Jan. 17	RE
S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	Jan. 17	MT
Moderna Gets $590 Million of Federal Funding For Influenza Vaccines	Jan. 17	DJ
Berenberg Bank Adjusts Moderna Price Target to $33 From $42, Maintains Hold Rating	Jan. 16	MT
Banks, bulls and tame inflation	Jan. 16
Analyst recommendations: Datadog, Estee Lauder, Netflix, Moderna, EasyJet...	Jan. 16
Moderna Struggles with COVID-19 Vaccine Market Share, Pipeline Progress, Morgan Stanley Says	Jan. 15	MT
Wall Street rallies on inflation and earnings bonanza	Jan. 15
Morgan Stanley Cuts Price Target on Moderna to $38 From $70, Keeps Equalweight Rating	Jan. 15	MT
Analyst recommendations: Adobe, Intuit, XPO, Netflix, Tesla...	Jan. 15
Leerink Partners Adjusts Moderna Price Target to $27 From $31, Maintains Underperform Rating	Jan. 14	MT
Stocks Gain Pre-Bell Ahead of Latest PPI Report; Asia, Europe Strong	Jan. 14	MT
MODERNA : Oddo BHF lowers its target price	Jan. 14	CF
Moderna, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:45 PM	Jan. 13
Stocks end mixed as US yields stay elevated	Jan. 13	RE
Health Care Climbs Amid Deal Activity - Health Care Roundup	Jan. 13	DJ
Equities Close Mixed as Traders Await Inflation Data, Bank Earnings	Jan. 13	MT
Equities Close Mixed as Traders Await Inflation Data, Bank Earnings	Jan. 13	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Jan. 13	MT
US Equities Markets End Mixed Monday as Traders Await Key Data, Earnings	Jan. 13	MT
Equities Mixed Intraday as Markets Await Bank Earnings, Inflation Data	Jan. 13	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	Jan. 13	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Call

More about the company